166 related articles for article (PubMed ID: 37061413)
21. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
Paik J; Dhillon S
Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
[TBL] [Abstract][Full Text] [Related]
22. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
[TBL] [Abstract][Full Text] [Related]
23. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
Yamamoto Y; Okamoto I; Otsubo K; Iwama E; Hamada N; Harada T; Takayama K; Nakanishi Y
Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
[TBL] [Abstract][Full Text] [Related]
24. Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancer.
Sentana-Lledo D; Viray H; Piper-Vallillo AJ; Widick P; Rangachari D; Wilson JL; Gangadharan SP; Aronovitz JA; Berman SM; VanderLaan PA; Costa DB
Lung Cancer; 2022 Oct; 172():124-126. PubMed ID: 36075183
[TBL] [Abstract][Full Text] [Related]
25. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
[TBL] [Abstract][Full Text] [Related]
26. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
[TBL] [Abstract][Full Text] [Related]
27. Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment.
Ohtaki Y; Shimizu K; Suzuki H; Suzuki K; Tsuboi M; Mitsudomi T; Takao M; Murakawa T; Ito H; Yoshimura K; Okada M; Chida M;
Lung Cancer; 2021 Mar; 153():108-116. PubMed ID: 33482408
[TBL] [Abstract][Full Text] [Related]
28. Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.
McKeage K
Drugs; 2015 Jan; 75(1):75-82. PubMed ID: 25428710
[TBL] [Abstract][Full Text] [Related]
29. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
30. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.
Santarpia M; Altavilla G; Rosell R
Expert Rev Respir Med; 2015 Jun; 9(3):255-68. PubMed ID: 25652176
[TBL] [Abstract][Full Text] [Related]
31. Alectinib in the treatment of ocular metastases of ALK rearranged non small cell lung cancer: Description of 2 case reports.
Gozzi E; Angelini F; Rossi L; Leoni V; Trenta P; Cimino G; Tomao S
Medicine (Baltimore); 2020 Jul; 99(27):e21004. PubMed ID: 32629718
[TBL] [Abstract][Full Text] [Related]
32. Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report.
Wang LM; Zhao P; Sun XQ; Yan F; Guo Q
World J Clin Cases; 2023 Aug; 11(22):5322-5328. PubMed ID: 37621597
[TBL] [Abstract][Full Text] [Related]
33. Alectinib for ALK-positive non-small-cell lung cancer.
Rossi A
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1005-13. PubMed ID: 27232673
[TBL] [Abstract][Full Text] [Related]
34. Successful alectinib desensitization in a patient with anaplastic lymphoma kinase-positive adenocarcinoma of the lung and alectinib-induced drug rash.
Anderson BE; Luczak TS; Ries LM; Hoefs GE; Silva-Benedict AC
J Oncol Pharm Pract; 2020 Dec; 26(8):2028-2030. PubMed ID: 32476587
[TBL] [Abstract][Full Text] [Related]
35. Proteasome Inhibition Overcomes ALK-TKI Resistance in
Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
[TBL] [Abstract][Full Text] [Related]
36. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
Popat S; Liu G; Lu S; Song G; Ma X; Yang JC
Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676
[TBL] [Abstract][Full Text] [Related]
37. Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.
Jahanzeb M; Lin HM; Pan X; Yin Y; Wu Y; Nordstrom B; Socinski MA
Oncologist; 2020 Oct; 25(10):867-877. PubMed ID: 32490560
[TBL] [Abstract][Full Text] [Related]
38. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
Katayama R; Friboulet L; Koike S; Lockerman EL; Khan TM; Gainor JF; Iafrate AJ; Takeuchi K; Taiji M; Okuno Y; Fujita N; Engelman JA; Shaw AT
Clin Cancer Res; 2014 Nov; 20(22):5686-96. PubMed ID: 25228534
[TBL] [Abstract][Full Text] [Related]
39. Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.
Lin JJ; Kennedy E; Sequist LV; Brastianos PK; Goodwin KE; Stevens S; Wanat AC; Stober LL; Digumarthy SR; Engelman JA; Shaw AT; Gainor JF
J Thorac Oncol; 2016 Nov; 11(11):2027-2032. PubMed ID: 27544060
[TBL] [Abstract][Full Text] [Related]
40. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
Ma HC; Liu YH; Ding KL; Liu YF; Zhao WJ; Zhu YJ; Chang XS; Chen YD; Xiao ZZ; Yu YY; Zhou R; Zhang HB
BMC Cancer; 2021 Nov; 21(1):1278. PubMed ID: 34836510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]